Circulating Angiogenic Factors and the Risk of Preeclampsia

By R. Gaiser. 2005

1,052 citations recorded by the source corpus.

Subfields: Immunology, Obstetrics and Gynecology

View Paper: https://www.semanticscholar.org/paper/5b666f1d2994c4e2ff4030ddc73174da5ddac004

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. M. Shibuya
2. Neil Perkins
3. Enrique F. Schisterman

In Obstetrics and Gynecology

1. Neil Perkins
2. Enrique F. Schisterman
3. M. Shibuya

Citations in the corpus

• The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. (2006, methodology): “Although the cause remains unclear, the syndrome may be initiated by placental factors that enter the maternal circulation and cause endothelial dysfunction, resulting in hypertension and proteinuria (12).”
• Inflammation and Pregnancy (2006, background): “Increases in circulating sFlt-1 levels are an early sign of impending preeclampsia.(44) Nuclear factor- B(NF- B) is a critical transcriptional activator of HIF-1a and basal NF- B activity is required for HIF-1a protein accumulation under hypoxia.”
• VEGF receptor signalling ? in control of vascular function (2006, background): “On the other hand, elevated production of the soluble VEGFR1 variant (sFlt1) in the placenta and consequent immobilization of VEGFA and decreased VEGFR2 signalling is implicated in preeclampsia”
• Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. (2013, background): “In 2003–2004, several researchers reported that an abnormal increase in the level of serum sFlt-1 in pregnant mothers is well correlated with the degree of PE (38-40) (Fig.”
• Trophoblast differentiation during embryo implantation and formation of the maternal-fetal interface. (2004, background): “levels of soluble VEGFR-1 and reduced levels of PlGF predict the subsequent development of preeclampsia (124, 125).”
• Risk Factors Associated with Acute Pyelonephritis in Healthy Women (2005, background): “In our previous study of serum concentrations of angiogenic proteins, serum free PlGF was lower in cases than in controls beginning at 13 to 16 weeks of gestation, becoming even lower after 25 weeks of gestation.(5) As predicted from serum measurements, in the current study, urinary PlGF at 21 to 32”
• Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia (2012, neutral): “82) <34 Weeks sFlt1 (pg/ml) 2,076 (1,439 - 3,007) 10,509 (7,309 - 15,585) 0.”